爱尔眼科：以高质量发展为指针，稳健推进网络布局

证券之星04-29 15:07

证券之星消息，爱尔眼科(300015)04月29日在投资者关系平台上答复投资者关心的问题。

投资者提问：爱尔眼科业绩连年下滑，为什么还要扩张，你的商誉留着散户给你承担吗，我20年买入的，被你坑惨了，请详细写明未来扩张计划及公司如何保证中小投资者的利益公平

爱尔眼科回复：谢谢关注！股票买入时点由投资者自身决定。无论早晚、多少，公司都赤诚相待，一视同仁。公司经营业绩系公开数据，敬请查阅。公司以高质量发展为指针，稳健推进网络布局，每年对商誉进行严格减值测试。公司积极保护投资者，特别是中小投资者的合法权益，通过稳健经营、持续分红回报投资者，已连续十年获交易所信息披露A级。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2631256180?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-29 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631256180","market":"fut","top_or_hot":-1,"title":"爱尔眼科：以高质量发展为指针，稳健推进网络布局","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300015\">爱尔眼科</a>(300015)04月29日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：爱尔眼科业绩连年下滑，为什么还要扩张，你的商誉留着散户给你承担吗，我20年买入的，被你坑惨了，请详细写明未来扩张计划及公司如何保证中小投资者的利益公平</p><p>爱尔眼科回复：谢谢关注！股票买入时点由投资者自身决定。无论早晚、多少，公司都赤诚相待，一视同仁。公司经营业绩系公开数据，敬请查阅。公司以高质量发展为指针，稳健推进网络布局，每年对商誉进行严格减值测试。公司积极保护投资者，特别是中小投资者的合法权益，通过稳健经营、持续分红回报投资者，已连续十年获交易所信息披露A级。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/51201020260428.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱尔眼科：以高质量发展为指针，稳健推进网络布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱尔眼科：以高质量发展为指针，稳健推进网络布局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 15:07 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026042900044202.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，爱尔眼科(300015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：爱尔眼科业绩连年下滑，为什么还要扩张，你的商誉留着散户给你承担吗，我20年买入的，被你坑惨了，请详细写明未来扩张计划及公司如何保证中小投资者的利益公平爱尔眼科回复：谢谢关注！股票买入时点由投资者自身决定。无论早晚、多少，公司都赤诚相待，一视同仁。公司经营业绩系公开数据，敬请查阅。公司以高质量发展为...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026042900044202.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://stock.stockstar.com/RB2026042900044202.shtml","article_id":"2631256180","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631256180","pubTimestamp":1777446434,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，爱尔眼科04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：爱尔眼科业绩连年下滑，为什么还要扩张，你的商誉留着散户给你承担吗，我20年买入的，被你坑惨了，请详细写明未来扩张计划及公司如何保证中小投资者的利益公平爱尔眼科回复：谢谢关注！公司以高质量发展为指针，稳健推进网络布局，每年对商誉进行严格减值测试。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300015":"爱尔眼科","BK0077":"质押式回购","BK0196":"行业龙头","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0188":"融资融券","BK0028":"国家队","BK0113":"养老产业","BK0200":"360概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK0096":"民营医院","BK0236":"卫生","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","BK0114":"健康中国","BK0012":"证金概念","LU1146622755.USD":"安本中国A股股票基金A Acc"},"translate_title":"Aier Ophthalmology: Steadily promoting network layout with high-quality development as a guide","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300015":1.5},"content_text":"证券之星消息，爱尔眼科(300015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：爱尔眼科业绩连年下滑，为什么还要扩张，你的商誉留着散户给你承担吗，我20年买入的，被你坑惨了，请详细写明未来扩张计划及公司如何保证中小投资者的利益公平爱尔眼科回复：谢谢关注！股票买入时点由投资者自身决定。无论早晚、多少，公司都赤诚相待，一视同仁。公司经营业绩系公开数据，敬请查阅。公司以高质量发展为指针，稳健推进网络布局，每年对商誉进行严格减值测试。公司积极保护投资者，特别是中小投资者的合法权益，通过稳健经营、持续分红回报投资者，已连续十年获交易所信息披露A级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631256180","isCrawlerRequest":true}